Simris Alg AB (publ), a European biologics company that focuses on extracting high-value biological active compounds from microalgae and cyanobacteria, has announced a framework collaboration agreement with Lonza Ltd. The collaboration is aimed at commercializing Simris' ADC payload platform, which is promising as effective cancer therapeutics that could improve quality of life for cancer patients. The agreement will enable Lonza to integrate Simris' ADC payload technology into the Lonza Bioconjugation Toolbox and offer it exclusively to new and existing customers seeking novel payloads to develop into ADC medicines. In return, Simris will promote Lonza to customers as its exclusive contract drug and manufacturing organization (CDMO) partner for services using its ADC technology. This strategic partnership will help Simris to reach new customers and Lonza's market-leading capabilities as a CDMO increase the likelihood that Simris' payloads will reach clinical use and improve the quality of life for cancer patients.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!